» Authors » Manuel Suarez-Tembra

Manuel Suarez-Tembra

Explore the profile of Manuel Suarez-Tembra including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 16
Citations 56
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Marco-Benedi V, Sanchez-Hernandez R, Diaz J, Jarauta E, Suarez-Tembra M, Pinto X, et al.
Lipids Health Dis . 2024 Sep; 23(1):290. PMID: 39256734
Background: Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) have represented an important change in the management of hypercholesterolemia, although, until now, they have barely been used. Without PCSK9i, many patients...
2.
Climent E, Gonzalez-Guerrero A, Marco-Benedi V, Garcia-Andreu M, Mediavilla-Garcia J, Suarez-Tembra M, et al.
Int J Mol Sci . 2024 May; 25(9). PMID: 38732050
Despite elevated low-density lipoprotein (LDL) cholesterol levels, some older subjects with heterozygous familial hypercholesterolemia (HeFH) do not develop atherosclerotic cardiovascular disease (ACVD) during their lifetime. The factors related to this...
3.
Delgado-Lista J, Mostaza J, Arrobas-Velilla T, Blanco-Vaca F, Masana L, Pedro-Botet J, et al.
Clin Investig Arterioscler . 2024 Apr; 36(4):243-266. PMID: 38599943
The irruption of lipoprotein(a) (Lp(a)) in the study of cardiovascular risk factors is perhaps, together with the discovery and use of proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor drugs, the...
4.
Climent E, Millan J, Ascaso J, Suarez-Tembra M, Morillas C, Civeira F, et al.
Lipids . 2023 Jun; 58(4):197-206. PMID: 37291984
Extremely variable prevalence rates of atherogenic dyslipidaemia (AD) in type 2 diabetes (T2DM) subjects have been reported. The primary aim was to assess AD prevalence in Spanish T2DM subjects. Secondary...
5.
Jimenez A, Vinals C, Marco-Benedi V, Gonzalez P, Domenech M, Suarez-Tembra M, et al.
J Am Coll Cardiol . 2023 Jan; 81(2):203-205. PMID: 36631212
No abstract available.
6.
Trias F, Pinto X, Corbella E, Suarez-Tembra M, Ruiz-Garcia A, Diaz-Diaz J, et al.
Med Clin (Barc) . 2021 Sep; 158(11):531-539. PMID: 34517987
Introduction: Statins are used with the understanding that a slightly increased risk of diabetes is outweighed by their cardiovascular benefits. However, it may be necessary to reconsider whether statin therapy...
7.
Climent E, Marco-Benedi V, Benaiges D, Pinto X, Suarez-Tembra M, Plana N, et al.
Nutr Metab Cardiovasc Dis . 2021 Mar; 31(5):1594-1603. PMID: 33744038
Background And Aims: Cardiovascular risk in heterozygous familial hypercholesterolaemia (HeFH) is driven by LDL cholesterol levels. Since lipid response to statin therapy presents individual variation, this study aimed to compare...
8.
Climent E, Bea A, Benaiges D, Brea-Hernando A, Pinto X, Suarez-Tembra M, et al.
Cardiovasc Drugs Ther . 2021 Feb; 36(2):301-308. PMID: 33555511
Purpose: Low-density lipoprotein (LDL) cholesterol reduction by statin therapy is dose-dependent, varies among different statins, and has wide inter-individual variability. The present study aimed to compare mean LDL cholesterol reduction...
9.
Marco-Benedi V, Laclaustra M, Bea A, Suarez-Tembra M, Plana N, Pinto X, et al.
Atherosclerosis . 2021 Feb; 320:47-52. PMID: 33529866
Background And Aims: Familial hypercholesterolemia (FH) is a codominant autosomal disease characterized by a high risk of cardiovascular disease when not in lipid-lowering treatment. However, there is a large variability...
10.
Perez-Calahorra S, Civeira F, Guallar-Castillon P, Pinto X, Banegas J, Pedro-Botet J, et al.
Eur J Prev Cardiol . 2020 Jan; 27(15):1649-1660. PMID: 31914797
A low prevalence of type 2 diabetes mellitus has been reported in familial hypercholesterolaemia. Whether a healthier lifestyle could explain it has not been explored. This cross-sectional study determines the...